BioCentury | Feb 21, 2019
Translation in Brief

Bugging inflammation in lung cancer

An MIT study linking the lung microbiome to inflammation offers new therapeutic strategies for treating lung cancer and a mechanistic rationale for testing cytokine inhibitors in the disease, a tack Novartis AG (NYSE:NVS; SIX:NOVN) has...
BioCentury | Feb 20, 2019
Distillery Therapeutics

Cancer

INDICATION: Lung cancer Patient samples and mouse studies suggest an antibiotic cocktail or inhibiting IL22RA1 or IL-17A could help treat lung cancer. In tissue samples from patients with lung adenocarcinoma, levels of IL22RA1 were higher...
BioCentury | May 30, 2018
Distillery Therapeutics

Cancer

INDICATION: Lung cancer Patient sample and mouse studies suggest inhibiting IL-22 could help treat KRAS-mutant lung cancer. In KRAS-mutant lung adenocarcinoma patients, high tumor levels of the IL-22 receptor IL22RA1 were associated with poor recurrence-free...
BioCentury | May 17, 2018
Preclinical News

Inhibiting IL-22 could treat KRAS-mutant lung cancer

A study published in Cancer Immunology Research from scientists at the University of Texas MD Anderson Cancer Center suggests inhibiting IL-22 could help treat KRAS-mutant lung cancer. High levels of IL-22 and IL-22-positive cells in...
BioCentury | Nov 3, 2016
Translation in Brief

The I’s have it

...anti-inflammatory drugs targeting tumor necrosis factor α (TNFα) work in part by downregulating interleukin-22 receptor subunit alpha 2 (IL22RA2; IL-22BP...
...Targeting IL22RA2 could have advantages over inhibiting TNFα or delivering recombinant IL-22. To investigate how IL22RA2...
...patent covering an IL22RA2-based diagnostic. Pelczar, P., et al. “A pathogenic role for T cell-derived IL-22BP...
Items per page:
1 - 5 of 5